Product Code: RP-ID-10086052 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10086052
Market Overview:
Global Sterile Injectables Market - Analysis By Molecule Type, Drug Type, Indication, Distribution Channel, By Region, By Country (2018 Edition): Forecast to 2030- Molecule Type (Biologic, Small Molecule), Drug Type (Monoclonal Antibody, Insulin, Vaccine, Fusion Protein, Immunoglobulin), Indication (Disorders - Oncological, Cardiovascular, Neurological, Infectious, Metabolic, Musculoskeletal), Channel (Hospital Pharmacy, Retail Pharmacy, E-commerce) 2022-2030
"The sterile injectables market is anticipated to expand at a CAGR of ~8% over the period 2022-2030. In the next eight years, the cancer application segment of the global sterile injectable drug market is expected to record a compound annual growth rate of 7%. The availability of broader treatment options and the increase in cancer prevalence are expected to drive growth. The market demand for injection of anti-cancer drugs is higher than expected during the period.
Taking into account the BPS analysis, by the end of 2020, the cancer department is estimated to account for more than 11% of the global sterile injectable drug market revenue share. Considering that with year-on-year growth and absolute dollar opportunities, the cancer segment is expected to create an absolute dollar opportunity of more than 3 billion U.S. dollars in 2017 compared to 2016. By the end of 2030, the cancer segment is expected to be close to a value of ~USD 120 billion, growing at a compound annual growth rate of 7% during the forecast period. Compared with 2016, by the end of 2024, the cancer sector revenue of the global sterile injectable drug market is expected to increase by 1.7 times.
THE RISE IN THE GLOBAL PREVALENCE OF CANCER MAY DRIVE THE GLOBAL MARKET FOR STERILE INJECTABLE DRUGS:
It is expected that the global increase in the prevalence of chronic diseases (especially cancer) will drive the demand for sterile injectable drugs during the forecast period. More and more drug manufacturers are focusing on the production of drugs for the treatment of cancer, which has also stimulated the sterile injection drug market. The FDAs rapid approval of sterile injectable drugs, coupled with the shortened approval time for the development of new drugs for the treatment of cancer, will help accelerate the supply of drugs and ultimately drive the global market;s demand for sterile injectable drugs.
IT IS EXPECTED THAT HIGH OPERATING COSTS AND PRODUCT SHUTDOWNS WILL HINDER GROWTH IN THE GLOBAL STERILE INJECTABLE DRUG MARKET:
high operating costs and the shutdown of injectable anticancer drugs are hindering global revenue growth. Sterile medicines require complex equipment to manufacture. Each sterile drug needs to be properly certified and sterilized before it is manufactured. This leads to high operating costs and high debt levels. In addition, because the FDA maintains a high degree of caution in the manufacturing, packaging, storage and distribution of sterile injectable drugs, the burden of regulatory costs is also high, which is a factor hindering the companys revenue growth. Sterile injection drug market. Competition from low-cost manufacturers has led to the discontinuation of many products in the cancer field. In addition, the integration of supply chains by large pharmaceutical companies has led to the closure of their existing manufacturing plants. This particular factor has a negative impact on the cancer field and the subsequent global sterile injectable drug market.
STRATEGIES OF MAJOR PLAYERS IN THE GLOBAL STERILE INJECTION MARKET :
Companies operating in the global sterile injection market are striving to consolidate their market position by acquiring large and small injection companies in the market. The company also focuses on improving manufacturing capabilities to achieve greater economies of scale, and targeting various global markets to enhance its geographic distribution in the global sterile injectable drug market."
Sanofi, Pfizer, Baxer International, Glaxo smith kline, Novartis, Gilead Sciences, Merck & Co., Astra Zeneca
Related Reports
Proof of Quality & Reliability
